Epithalon

Epitalon—alternatively spelled Epithalon and also referred to as Epitalamin synthetic peptide—is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, modeled on a partial sequence of epithalamin, a naturally occurring polypeptide extract derived from the bovine pineal gland that has been studied since the 1960s. The compound was developed and extensively characterized by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, representing one of the most studied "peptide bioregulator" series in the Eastern European research literature. Unlike most peptides in the research marketplace that act at named cell-surface receptors with well-defined pharmacological profiles, epitalon's proposed mechanisms center on chromatin regulation, telomere biology, and neuroendocrine modulation of the pineal axis—areas where the data are substantial by bioregulator standards but remain less mature than receptor pharmacology-based compounds. Nevertheless, epitalon has attracted growing attention in the Western research community following publication of telomerase activation data in human somatic cells and a series of controlled longevity studies in rodent models. Peptides.SO aggregates 93 supplier listings for Epitalon from 74 distinct vendors, making it among the most widely stocked peptide bioregulators on the platform. Offered strictly for in vitro and preclinical laboratory research under Research Use Only (RUO) conditions.

Molecular Properties and Structure:

Epitalon (Ala-Glu-Asp-Gly; molecular formula C14H22N4O9; MW 394.34 Da) is an acidic tetrapeptide with a net negative charge at physiological pH due to its two dicarboxylic amino acids (glutamic acid and aspartic acid). This charge profile may contribute to DNA binding through electrostatic interactions with histone proteins or regulatory chromatin domains. The small size and amphipathic character of the peptide allow it to traverse nuclear pores and interact directly with chromatin; this nuclear localization distinguishes it from large receptor-binding peptides that transduce signals from the cell surface. The amino acid sequence Ala-Glu-Asp-Gly is found in certain endogenous proteins involved in transcriptional regulation, and Khavinson's group proposed that its effects on gene expression represent a "peptide regulatory" mechanism analogous to but more sequence-specific than the general effects of histones or other chromatin-binding factors.

Mechanism of Action:

The most widely cited mechanism for epitalon is telomerase activation in somatic cells. Telomerase (hTERT-containing ribonucleoprotein complex) elongates telomeric repeat sequences (TTAGGG) at chromosome ends that shorten with each cell division in non-stem somatic cells. Khavinson et al. (2003) reported that epitalon at 0.1–10 nM concentrations activated telomerase in human fetal fibroblasts and somatic cell lines and produced measurable telomere elongation over 3-week treatment protocols, an effect not previously demonstrated for a synthetic peptide of this class. The proposed upstream mechanism involves epitalon binding to regulatory DNA sequences in the hTERT promoter region, increasing hTERT mRNA transcription in a manner analogous to transcription factor binding. Additional proposed mechanisms include: normalization of melatonin secretion through pinealocyte stimulation (melatonin synthesis enzyme induction), suppression of cortisol-mediated stress signaling that accelerates telomere attrition, and direct antioxidant activity through reduction of lipid peroxidation markers in aged cell models. The relative contributions of these mechanisms to the compound's biological effects in vivo remain an active area of research.

Key Research Studies:

Khavinson VKh et al. (2003) published the foundational molecular biology paper demonstrating that epitalon at 0.1 and 1.0 nM activated telomerase (measured by TRAP assay) in primary human fetal fibroblasts and somatic cell lines, with telomere length measured by Southern blot increasing over 3-week treatment windows. This paper remains the primary molecular mechanism reference for epitalon research. (PMID 12937682)

Kossoy G et al. (2009) conducted a long-term rodent survival study showing that rats treated with epitalon had significantly extended maximum lifespan compared to controls (147 vs. 127 weeks median survival in female SHR rats), with concurrent reductions in the incidence of spontaneous tumors, particularly mammary adenocarcinomas. The study also documented normalization of estrogen cycle parameters consistent with pineal axis modulation. (PMID 19842398)

Yue X et al. (2022) demonstrated in a contemporary cell biology study that epitalon treatment protected mouse oocytes from post-ovulatory oxidative aging in vitro, reducing markers of oxidative damage (reactive oxygen species, malondialdehyde), preserving mitochondrial membrane potential, and maintaining spindle morphology in a dose-dependent manner (1–10 nM), with effects attributed to antioxidant signaling and HSP70 upregulation. (PMID 35413689)

Goncharova ND et al. (2014) evaluated epitalon's effects on the hypothalamic-pituitary-adrenal (HPA) axis in aging Macaca mulatta (rhesus macaques), demonstrating that epitalon administration (10 μg/day for 30 days) normalized morning cortisol peaks that were elevated in aged animals, and partially restored blunted ACTH responses to CRH challenge, consistent with neuroendocrine rejuvenation of the HPA axis. (PMID 24455544)

Khavinson V and Linkova N (2020) published a systematic review of the pineal peptide bioregulator series including epitalon across 25 years of research, summarizing controlled animal data showing effects on longevity, tumor incidence, circadian rhythm normalization, and pineal melatonin restoration in models of aging, and calling for double-blind human clinical trials as the next step in translational validation. (PMID 32660402)

Research Applications:

- Telomere biology and cellular senescence: TRAP assay telomerase activation, telomere length quantification by qPCR-based methods - Pineal gland physiology and circadian biology: melatonin synthesis modulation, arylalkylamine N-acetyltransferase (AANAT) activity - Oocyte aging and reproductive biology: post-ovulatory aging models, mitochondrial function assays - HPA axis modulation: cortisol and ACTH stress response studies in aging rodent and primate models - Tumor suppression research: spontaneous mammary tumor incidence in aging rodent cohorts - Oxidative stress and mitochondrial aging: ROS, MDA, mitochondrial membrane potential assays - Comparative peptide bioregulator research: epitalon alongside thymalin (thymic bioregulator), vilon (liver bioregulator), and other Khavinson-series peptides - Age-associated gene expression: transcriptomic profiling in epitalon-treated primary cells

Typical Research Concentrations:

In vitro telomerase activation assays (TRAP) use epitalon at 0.01–10 nM in primary human fibroblasts and somatic cell lines. Oocyte aging protection assays use 1–10 nM concentrations in M2 medium over 24-hour post-ovulatory incubation periods. Antioxidant and mitochondrial function assays typically use 5–50 nM in cell culture. In vivo rodent studies use 1–10 μg/day subcutaneous injection over periods of weeks to months; primate studies used 10 μg/day for 30-day cycles.

Safety Profile from Published Research:

Across the published literature spanning 25+ years of Khavinson laboratory work, epitalon has been administered to rodents, primates, and in limited clinical contexts without reported organ toxicity or genotoxic signals. Long-term administration (52-week rodent survival studies) showed no pathological changes attributable to epitalon in tissue histopathology. In the macaque study, no adverse biochemical or hematological changes were detected at 10 μg/day dose. The absence of a defined cell-surface receptor with established pharmacodynamic monitoring endpoints means that off-target effects may be difficult to detect in short-term assays. Researchers should use concurrent positive and negative controls and appropriate dose-response characterization given the compound's unusual chromatin-level mechanism.

For Research Use Only (RUO). Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. All laboratory use must comply with applicable institutional review and biosafety requirements.